Efficacy and safety of add-on treatment with finerenone in patients with diabetic kidney disease already treated with SGLT-2 inhibitors
Clinical Nephrology · 2025
DOI: 10.5414/cnp104s16 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Nephrology, 2025. Verfasst von Manja Antonič und 3 weiteren Autor:innen. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetic Nephropathies, Naphthyridines, Mineralocorticoid Receptor Antagonists. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Antonič, M., Adamlje, A., Leskovar, B., & Fornazarič, D. (2025). Efficacy and safety of add-on treatment with finerenone in patients with diabetic kidney disease already treated with SGLT-2 inhibitors. Clinical Nephrology. https://doi.org/10.5414/cnp104s16
Vancouver
Antonič M, Adamlje A, Leskovar B, Fornazarič D. Efficacy and safety of add-on treatment with finerenone in patients with diabetic kidney disease already treated with SGLT-2 inhibitors. Clinical Nephrology. 2025. doi:10.5414/cnp104s16
BibTeX
@article{Antoni2025,
author = {Antonič, Manja and Adamlje, Anton and Leskovar, Boštjan and Fornazarič, Denis},
title = {Efficacy and safety of add-on treatment with finerenone in patients with diabetic kidney disease already treated with SGLT-2 inhibitors},
journal = {Clinical Nephrology},
year = {2025},
doi = {10.5414/cnp104s16}
}
EUVIMED